Active ingredients: methylphenidate
What it is used for
Attention deficit hyperactivity disorder (ADHD). ADHD was previously known as attention deficit disorder. Other terms being used to describe this behavioural syndrome include minimal brain dysfunction in children, hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction, and psycho-organic syndrome of children. Attenta is indicated as part of a comprehensive treatment program which typically includes other remedial measures (psychological, educational, social) for achieving a beneficial effect in children with a behavioural syndrome characterised by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity (not always present) and impulsivity. The diagnosis of this syndrome should not be made when these symptoms are only of recent origin. Non-localising (soft) neurological signs, emotional lability, learning disability and an abnormal electroencephalogram (EEG) may or may not be present, and a diagnosis of CNS dysfunction may or may not be warranted. Special diagnostic considerations for ADHD. The aetiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but also of psychological, educational and social resources. Characteristics commonly reported include chronic history or short attention span, distractibility, emotional lability, impulsivity, moderate to severe hyperactivity, minor neurological signs and an abnormal EEG. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics. Drug treatment is not indicated for all children with this syndrome. Stimulants are not intended for use in children who exhibit symptoms secondary to environmental factors (eg. child abuse in particular) or primary psychiatric disorders. Appropriate educational placement is essential and psychosocial intervention is generally necessary. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the doctor's assessment of the chronicity and severity of the child's symptoms. Narcolepsy. The symptoms include daytime sleepiness, inappropriate sleep episodes and rapidly occurring loss of voluntary muscle tone. Effective for symptoms of sleepiness but not for loss of voluntary muscle tone.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 25 degrees Celsius
- Shelf lifetime is 18 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
7mm white flat bevel edged tablet, debossed with "MP" and "10" either side of a central breakline on one side, and "Greek Alpha Symbol" on the reverse.
Do I need a prescription?
This medicine requires authorisation for prescription from your doctor. It is
Pregnant or planning a pregnancy?
For the active ingredient methylphenidate
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems